{"id":"NCT00805766","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)","officialTitle":"Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650 in Patients With Crohn's Disease (CD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2009-11","completion":"2010-07","firstPosted":"2008-12-10","resultsPosted":"2012-12-05","lastUpdate":"2018-02-09"},"enrollment":39,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"TA-650","otherNames":["Infliximab"]}],"arms":[{"label":"TA-650","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy, safety and pharmacokinetics after administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an insufficient response to previous treatment with 5 mg/kg of REMICADE every 8 weeks.","primaryOutcome":{"measure":"Median Crohn's Disease Activity Index (CDAI) Change From Week 0 to Week 8 in the Increased Dose Period","timeFrame":"Increased Dose Period (Week 0 to Week 8)","effectByArm":[{"arm":"TA-650","deltaMin":95,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":45},"commonTop":["DNA antibody positive","Nasopharyngitis","Oropharyngeal pain","Headache","Influenza"]}}